ArticleEuropean journal of medical research2025
Performance and comparison of FLCCheck: a novel serum free light chain assay for the Auxiliary Diagnosis of Multiple Myeloma.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundMultiple myeloma (MM) is a malignant bone marrow disorder characterized by the abnormal proliferation of plasma cells. The measurement of serum free light chains (FLC) is a standard diagnostic and management tool for MM. The International Myeloma Working Group utilizes the iFLC/uFLC ratio to distinguish smoldering multiple myeloma (SMM) from active MM requiring therapeutic intervention.
objectivesWe employed a novel serum free light chain (FLC) assay kit, FLCCheck, to evaluate its consistency with established traditional methods. DESIGN AND
methodsWe collected 115 samples from 72 patients and tested them using FLCCheck, Freelite, and N Latex FLC. The data obtained from each method were analyzed using Passing-Bablok and Bland-Altman methods, and a chi-square analysis was performed to assess the consistency between the tests. Finally, we used the three methods to calculate and analyze the κ/λ ratio for two patients during their clinical treatment.
resultsThe FLCCheck assay demonstrated a validated linear range, high precision, and strong resistance to interference for both κ and λ light chain detection. By incorporating blocking peptides to reduce cross-reactivity, we improved the reliability of the diluted recovery by more than twofold. The results indicate that FLCCheck exhibits the highest correlation with N Latex FLC, particularly regarding the κ/λ ratio and κ FLC. We also monitored the therapeutic efficacy in MM patients, the results indicated that the three methods followed comparable trends; yet, FLCCheck distinguished itself by demonstrating a more rapid response with the highest amplitude variation.
conclusionsOur findings show satisfactory consistency between the three FLC testing methods, but their interchangeability is not recommended. Consistent use of the same assay method across all reports is essential. The development of new FLC detection methods is valuable for optimizing disease monitoring, prognosis, and the management of multiple myeloma and related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.